Sun Pharma Advanced Research Company Company Description

Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally.

It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications.

The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.

Sun Pharma Advanced Research Company Limited

Country	India
Founded	2006
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	279
CEO	Anilkumar Raghavan

Contact Details

Address: 17/B, Mahal Industrial Estate Mumbai, 400093 India
Phone	91 22 6645 5645
Website	sparc.life

Stock Details

Ticker Symbol	SPARC
Exchange	National Stock Exchange of India
Fiscal Year	April - March
Reporting Currency	INR
ISIN Number	INE232I01014
SIC Code	2834

Key Executives

Name	Position
Anilkumar Raghavan	Chief Executive Officer
Anup M. Rathi	Chief Financial Officer
Narendra Lakkad	Head of Corporate Development and Operations Management
Prasanna Deshmukh	Head of Human Resources and Administration
Jaydeep Issrani	Senior General Manager of Business Development, Corporate Communication and Investor Relations
Kajal K. Damania	Company Secretary and Compliance Officer
Dr. Nitin K. Damle Ph.D.	Head of Biologics
Dr. Yashoraj Zala	Senior Vice President and Head of Drug Delivery Systems
Dr. Vikram K. Ramanathan	Senior Vice President of Preclinical Development and Head of Translational Development
Dr. Venkata P. Palle	Executive Vice President of Small Molecule Therapeutics